Skip to content

Study · Randomized controlled trial · n = 230 · 2004

5 results

Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial.

Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM, Flamant Y, Fingerhut A, Fagniez PL, Chipponi J

Archives of surgery (Chicago, Ill. : 1960)1 Mar 2004Cited by 113 (Europe PMC)

PMID15006886 (opens in a new tab)DOI10.1001/archsurg.139.3.288 (opens in a new tab)PepBankPUB-15006886
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After pancreatic resection, intra-abdominal complications occurred in 22% with octreotide versus 32% of controls (P =.08).

    In plain wordsAfter pancreatic resection, complications occurred in 22% with octreotide versus 32% with control (P = 0.08).

    Peptide
    Octreotide
    Outcome
    DecreasePatients with intra-abdominal complications
    Study

    n = 230

    Comparator
    Control
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Patients with 1 or more intra-abdominal complications
    22%
    octreotide group (n = 122)
    Patients with 1 or more intra-abdominal complications
    32%
    control group (n = 108)

    Source sentences

    Summary
    Fewer patients (P =.08) in the octreotide group sustained 1 or more IACs (22% vs 32%).
    2 context sentences
    Summary · context
    Single-blind, controlled, randomized trial.
    Summary · context
    Of 230 randomized patients undergoing pancreatoduodenectomy and pancreatic enteric anastomosis or distal pancreatectomy for either malignant or benign tumor or chronic pancreatitis, 122 were allotted intraoperatively to receive octreotide; 108 served as controls.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After pancreatic resection, intra-abdominal complication severity did not differ significantly between octreotide and control.

    In plain wordsAfter pancreatic resection, complication severity did not differ significantly between octreotide and control.

    Peptide
    Octreotide
    Outcome
    No significant changeIntra-abdominal complication severity
    Study

    n = 230

    Comparator
    Control
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were found regarding IAC severity.
    2 context sentences
    Summary · context
    Single-blind, controlled, randomized trial.
    Summary · context
    Of 230 randomized patients undergoing pancreatoduodenectomy and pancreatic enteric anastomosis or distal pancreatectomy for either malignant or benign tumor or chronic pancreatitis, 122 were allotted intraoperatively to receive octreotide; 108 served as controls.
  3. 03HumanObservational studyEfficacy outcome

    After pancreatic resection with duct diameter less than 3 mm, octreotide was associated with fewer intra-abdominal complications versus control (P<.02).

    In plain wordsAfter pancreatic resection with a small duct, octreotide was linked to fewer complications than control.

    Peptide
    Octreotide
    Outcome
    DecreaseIntra-abdominal complications with duct less than 3 mm
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In subgroup analysis, octreotide significantly reduced the rate of patients sustaining 1 or more IACs when the main pancreatic duct diameter was less than 3 mm (P<.02), when pancreatojejunostomy was performed (P<.02), or both (P<.02).
    2 context sentences
    Summary · context
    Single-blind, controlled, randomized trial.
    Summary · context
    Of 230 randomized patients undergoing pancreatoduodenectomy and pancreatic enteric anastomosis or distal pancreatectomy for either malignant or benign tumor or chronic pancreatitis, 122 were allotted intraoperatively to receive octreotide; 108 served as controls.
  4. 04HumanObservational studyEfficacy outcome

    After pancreatojejunostomy, octreotide was associated with fewer intra-abdominal complications versus control (P<.02).

    In plain wordsAfter pancreatojejunostomy, octreotide was linked to fewer complications than control.

    Peptide
    Octreotide
    Outcome
    DecreaseIntra-abdominal complications after pancreatojejunostomy
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In subgroup analysis, octreotide significantly reduced the rate of patients sustaining 1 or more IACs when the main pancreatic duct diameter was less than 3 mm (P<.02), when pancreatojejunostomy was performed (P<.02), or both (P<.02).
    2 context sentences
    Summary · context
    Single-blind, controlled, randomized trial.
    Summary · context
    Of 230 randomized patients undergoing pancreatoduodenectomy and pancreatic enteric anastomosis or distal pancreatectomy for either malignant or benign tumor or chronic pancreatitis, 122 were allotted intraoperatively to receive octreotide; 108 served as controls.
  5. 05HumanObservational studyEfficacy outcome

    With duct diameter less than 3 mm and pancreatojejunostomy, octreotide was associated with fewer intra-abdominal complications versus control (P<.02).

    In plain wordsWith a small duct and pancreatojejunostomy, octreotide was linked to fewer complications than control.

    Peptide
    Octreotide
    Outcome
    DecreaseIntra-abdominal complications with small duct and pancreatojejunostomy
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In subgroup analysis, octreotide significantly reduced the rate of patients sustaining 1 or more IACs when the main pancreatic duct diameter was less than 3 mm (P<.02), when pancreatojejunostomy was performed (P<.02), or both (P<.02).
    2 context sentences
    Summary · context
    Single-blind, controlled, randomized trial.
    Summary · context
    Of 230 randomized patients undergoing pancreatoduodenectomy and pancreatic enteric anastomosis or distal pancreatectomy for either malignant or benign tumor or chronic pancreatitis, 122 were allotted intraoperatively to receive octreotide; 108 served as controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT06085976

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

Clinica Universidad de Navarra, Universidad de Navarran = 6214 Aug 2023 to est. 30 Nov 2025

Hepatic Carcinoma · Hepatic Metastasis

Trial pageClinicalTrials.govUpdated 17 Oct 2023
CompletedPhase 4NCT01301222

Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas

PVS Memorial Hospitaln = 110Sept 2010 to Feb 2015

Pancreatic Fistula

Trial pageClinicalTrials.govUpdated 24 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.